C. Vercherat

发表

Foxo3 Is Essential for the Regulation of Ataxia Telangiectasia Mutated and Oxidative Stress-mediated Homeostasis of Hematopoietic Stem Cells*

Sathish Kumar Mungamuri, S. K. Mungamuri, R. Taneja, 2008, Journal of Biological Chemistry.

Sharp-1 regulates TGF-&bgr; signaling and skeletal muscle regeneration

M. Rossner, Li Li, T. Chung, 2014, Journal of Cell Science.

Stra13 regulates satellite cell activation by antagonizing Notch signaling

Hong Sun, T. Thin, Li Li, 2007, The Journal of cell biology.

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

J. Scoazec, C. Vercherat, T. Walter, 2010, Neuroendocrinology.

O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents

V. Hervieu, J. Scoazec, C. Vercherat, 2015, British Journal of Cancer.

Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice

V. Hervieu, J. Scoazec, C. Vercherat, 2015, Cancer.

Neuropilin‐2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors

V. Hervieu, J. Scoazec, C. Vercherat, 2019, The Journal of pathology.

Stra13 regulates oxidative stress mediated skeletal muscle degeneration.

T. Chung, R. Taneja, S. Ghaffari, 2009, Human molecular genetics.

Sharp-1 regulates TGF-β signaling and skeletal muscle regeneration

M. Rossner, Li Li, T. Chung, 2014, Development.

mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines

J. Scoazec, C. Vercherat, T. Walter, 2017, Oncotarget.

The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors

V. Hervieu, J. Scoazec, C. Vercherat, 2015, Oncotarget.

Altered MENIN expression disrupts the MAFA differentiation pathway in insulinoma.

J. Scoazec, C. Vercherat, C. Pouponnot, 2013, Endocrine-related cancer.

Deregulation of genetic pathways in neuroendocrine tumors.

C. Vercherat, J. Chayvialle, A. Calender, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors

V. Hervieu, J. Scoazec, C. Vercherat, 2016, Investigational New Drugs.

MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells.

J. Scoazec, C. Vercherat, J. Chayvialle, 2008, Gastroenterology.

Functional characterization of a promoter region in the human MEN1 tumor suppressor gene.

C. Vercherat, M. Fromaget, J. Chayvialle, 2003, Journal of molecular biology.

Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein

C. Béroud, G. Lenoir, C. Vercherat, 2002, Human mutation.

Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells

V. Hervieu, J. Scoazec, C. Vercherat, 2017, Molecular Cancer Therapeutics.

Metabolic expressivity of human genetic variants: NMR metabotyping of MEN1 pathogenic mutants.

J. Scoazec, B. Elena-Herrmann, C. Vercherat, 2014, Journal of pharmaceutical and biomedical analysis.

Stra13 regulates satellite cell activation by antagonizing Notch signaling

Hong Sun, T. Thin, Li Li, 2007, The Journal of cell biology.